The potential of pamrevlumab in diseases with underlying mechanisms of fibrotic processes and its prospects in ophthalmology

Lely Retno Wulandari; Edwin Damar Prabowo; Happy Kurnia Permata Sari; Hidayat Sujuti; Sri Winarsih

doi:10.3897/pharmacia.72.e144964

The potential of pamrevlumab in diseases with underlying mechanisms of fibrotic processes and its prospects in ophthalmology

Lely Retno Wulandari^*
, Edwin Damar Prabowo
, Happy Kurnia Permata Sari
, Hidayat Sujuti
, Sri Winarsih

^*Corresponding author for this work

Faculty of Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

Introduction: Pamrevlumab, a monoclonal antibody targeting CTGF, is considered a potential therapy for eye diseases involving fibrosis. The aim of this study was to explore its potential in treating eye diseases. Methods: A systematic review was conducted following PRISMA guidelines, searching studies up to 2024 across various databases. Study quality was assessed using the Cochrane RoB 2.0 tool. Results: Pamrevlumab has the potential to slow fibrosis progression and improve organ function, although treatment responses varied. Two studies showed significant changes, while four did not. The risk of bias indicated varied methodological quality. Discussion: Pamrevlumab shows potential in treating fibrosis-related eye diseases by inhibiting CTGF. Further research is needed to assess its long0-term effects, safety, and dose optimization. Conclusion: Pamrevlumab shows significant potential in the treatment of chronic eye diseases, with promising safety outcomes based on previous experiences in DMD patients.

Original language	English
Journal	Pharmacia
Volume	72
DOIs	https://doi.org/10.3897/pharmacia.72.e144964
Publication status	Published - 2025

Keywords

connective tissue growth factor
fibrosis
monoclonal antibody
systematic review

Access to Document

10.3897/pharmacia.72.e144964

Cite this

@article{84acd7e33dbd4383a09608ff2ffb168d,

title = "The potential of pamrevlumab in diseases with underlying mechanisms of fibrotic processes and its prospects in ophthalmology",

abstract = "Introduction: Pamrevlumab, a monoclonal antibody targeting CTGF, is considered a potential therapy for eye diseases involving fibrosis. The aim of this study was to explore its potential in treating eye diseases. Methods: A systematic review was conducted following PRISMA guidelines, searching studies up to 2024 across various databases. Study quality was assessed using the Cochrane RoB 2.0 tool. Results: Pamrevlumab has the potential to slow fibrosis progression and improve organ function, although treatment responses varied. Two studies showed significant changes, while four did not. The risk of bias indicated varied methodological quality. Discussion: Pamrevlumab shows potential in treating fibrosis-related eye diseases by inhibiting CTGF. Further research is needed to assess its long0-term effects, safety, and dose optimization. Conclusion: Pamrevlumab shows significant potential in the treatment of chronic eye diseases, with promising safety outcomes based on previous experiences in DMD patients.",

keywords = "connective tissue growth factor, fibrosis, monoclonal antibody, systematic review",

author = "Wulandari, \{Lely Retno\} and Prabowo, \{Edwin Damar\} and Sari, \{Happy Kurnia Permata\} and Hidayat Sujuti and Sri Winarsih",

note = "Publisher Copyright: Copyright Wulandari LR et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.",

year = "2025",

doi = "10.3897/pharmacia.72.e144964",

language = "English",

volume = "72",

journal = "Pharmacia",

issn = "0428-0296",

publisher = "Pensoft Publishers",

}

TY - JOUR

T1 - The potential of pamrevlumab in diseases with underlying mechanisms of fibrotic processes and its prospects in ophthalmology

AU - Wulandari, Lely Retno

AU - Prabowo, Edwin Damar

AU - Sari, Happy Kurnia Permata

AU - Sujuti, Hidayat

AU - Winarsih, Sri

N1 - Publisher Copyright: Copyright Wulandari LR et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PY - 2025

Y1 - 2025

N2 - Introduction: Pamrevlumab, a monoclonal antibody targeting CTGF, is considered a potential therapy for eye diseases involving fibrosis. The aim of this study was to explore its potential in treating eye diseases. Methods: A systematic review was conducted following PRISMA guidelines, searching studies up to 2024 across various databases. Study quality was assessed using the Cochrane RoB 2.0 tool. Results: Pamrevlumab has the potential to slow fibrosis progression and improve organ function, although treatment responses varied. Two studies showed significant changes, while four did not. The risk of bias indicated varied methodological quality. Discussion: Pamrevlumab shows potential in treating fibrosis-related eye diseases by inhibiting CTGF. Further research is needed to assess its long0-term effects, safety, and dose optimization. Conclusion: Pamrevlumab shows significant potential in the treatment of chronic eye diseases, with promising safety outcomes based on previous experiences in DMD patients.

AB - Introduction: Pamrevlumab, a monoclonal antibody targeting CTGF, is considered a potential therapy for eye diseases involving fibrosis. The aim of this study was to explore its potential in treating eye diseases. Methods: A systematic review was conducted following PRISMA guidelines, searching studies up to 2024 across various databases. Study quality was assessed using the Cochrane RoB 2.0 tool. Results: Pamrevlumab has the potential to slow fibrosis progression and improve organ function, although treatment responses varied. Two studies showed significant changes, while four did not. The risk of bias indicated varied methodological quality. Discussion: Pamrevlumab shows potential in treating fibrosis-related eye diseases by inhibiting CTGF. Further research is needed to assess its long0-term effects, safety, and dose optimization. Conclusion: Pamrevlumab shows significant potential in the treatment of chronic eye diseases, with promising safety outcomes based on previous experiences in DMD patients.

KW - connective tissue growth factor

KW - fibrosis

KW - monoclonal antibody

KW - systematic review

UR - https://www.scopus.com/pages/publications/105016587131

U2 - 10.3897/pharmacia.72.e144964

DO - 10.3897/pharmacia.72.e144964

M3 - Review article

AN - SCOPUS:105016587131

SN - 0428-0296

VL - 72

JO - Pharmacia

JF - Pharmacia

ER -

The potential of pamrevlumab in diseases with underlying mechanisms of fibrotic processes and its prospects in ophthalmology

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this